Prevail's gene therapy Orphan drug in Europe for dementia type

 

• The European Commission has designated orphan designation to Prevail Therapeutics' (PRVL +1.2%) investigational AAV9 gene therapy, PR006 for the treatment of frontotemporal dementia with a GRN mutation (FTD-GRN)
• The Company expects to initiate enrollment in Phase 1/2 PROCLAIM trial of PR006 in next month, and anticipates to provide a biomarker and safety analysis on a subset of patients in the PROCLAIM trial in 2021.
• Earlier, the gene therapy received US Orphan Drug and Fast Track designation for the same indication.
• https://seekingalpha.com/news/3640000-prevails-gene-therapy-orphan-drug-in-europe-for-type-of-dementia